General Information of Drug (ID: DML3NEU)

Drug Name
RO-319790 Drug Info
Synonyms
Ro-31-9790; CHEMBL16520; Ro 31-9790; (R)-N1-((S)-3,3-dimethyl-1-(methylamino)-1-oxobutan-2-yl)-N4-hydroxy-2-isobutylsuccinamide; SCHEMBL4633699; QRXOZHSEEGNRFC-ZYHUDNBSSA-N; ZINC1534591; BDBM50063920; CS-6682; HY-101703
Indication
Disease Entry ICD 11 Status REF
Rheumatoid arthritis FA20 Terminated [1]
Cross-matching ID
PubChem CID
9904965
TTD Drug ID
DML3NEU

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Patented Agent(s)
Discontinued Drug(s)
Preclinical Drug(s)
Investigative Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Prinomastat DM9HOKG Lung cancer 2C25.0 Approved [3]
Marimastat DM6V34C Pancreatic cancer 2C10 Phase 3 [4]
CIPEMASTAT DM803GL Rheumatoid arthritis FA20 Phase 3 [5]
Apratastat DM8W4N9 Rheumatoid arthritis FA20 Phase 2 [6]
PMID29130358-Compound-Figure18(14a) DMHIBTZ N. A. N. A. Patented [7]
PMID29130358-Compound-Figure10(2a) DMFWXPS N. A. N. A. Patented [7]
BMS 275291 DMKSFPE Kaposi sarcoma 2B57 Discontinued in Phase 3 [8]
GM6001 DM7V9CT Corneal ulcer 9A76 Discontinued in Phase 2 [9]
RS-130830 DMOTANY Hepatitis C virus infection 1E51.1 Discontinued in Phase 2 [10]
XL784 DMICR39 Diabetic nephropathy GB61.Z Discontinued in Phase 2 [11]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Curcumin DMQPH29 Solid tumour/cancer 2A00-2F9Z Phase 3 [12]
DP-b99 DM97S10 Stroke 8B20 Phase 3 [13]
GS-5745 DMP8MDW Gastric adenocarcinoma 2B72 Phase 3 [14]
Andecaliximab DMLDB1X Gastric adenocarcinoma 2B72 Phase 3 [15]
BLZ-100 DMFKA4G Glioma 2A00.0 Phase 1/2 [16]
Neovastat DMXTYWJ Non-small-cell lung cancer 2C25.Y Phase 1 [17]
PMID29130358-Compound-Figure18(14a) DMHIBTZ N. A. N. A. Patented [7]
PMID29130358-Compound-Figure17(12) DMML4PA N. A. N. A. Patented [7]
PMID29130358-Compound-Figure17(10) DMVA15O N. A. N. A. Patented [7]
PMID29130358-Compound-SB-3CT DMC64XQ N. A. N. A. Patented [7]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
PMID29130358-Compound-Figure10(2a) DMFWXPS N. A. N. A. Patented [7]
GM6001 DM7V9CT Corneal ulcer 9A76 Discontinued in Phase 2 [9]
RS-130830 DMOTANY Hepatitis C virus infection 1E51.1 Discontinued in Phase 2 [10]
PG-530742 DMELXBQ Myocardial infarction BA41-BA43 Discontinued in Phase 2 [18]
Batimastat DM92VRP Idiopathic pulmonary fibrosis CB03.4 Preclinical [19]
SC-44463 DMBPNKT N. A. N. A. Terminated [20]
BB-1101 DM7GH5Z Multiple sclerosis 8A40 Terminated [21]
L-696418 DMV785R N. A. N. A. Terminated [22]
MMI270 DM38N2K Discovery agent N.A. Investigative [23]
IK-862 DMJA4UE Discovery agent N.A. Investigative [24]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Matrix metalloproteinase-1 (MMP-1) TTMX39J MMP1_HUMAN Inhibitor [2]
Matrix metalloproteinase-3 (MMP-3) TTUZ2L5 MMP3_HUMAN Inhibitor [2]
Matrix metalloproteinase-9 (MMP-9) TT6X50U MMP9_HUMAN Inhibitor [2]

References

1 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800002350)
2 The asymmetric synthesis and in vitro characterization of succinyl mercaptoalcohol and mercaptoketone inhibitors of matrix metalloproteinases. Bioorg Med Chem Lett. 1998 May 19;8(10):1163-8.
3 AG-3340 (Agouron Pharmaceuticals Inc). IDrugs. 2000 Mar;3(3):336-45.
4 Metalloelastase (MMP-12) induced inflammatory response in mice airways: effects of dexamethasone, rolipram and marimastat. Eur J Pharmacol. 2007 Mar 15;559(1):75-81.
5 Matrix metalloproteinase inhibition lowers mortality and brain injury in experimental pneumococcal meningitis. Infect Immun. 2014 Apr;82(4):1710-8.
6 Acetylenic TACE inhibitors. Part 3: Thiomorpholine sulfonamide hydroxamates. Bioorg Med Chem Lett. 2006 Mar 15;16(6):1605-9.
7 Gelatinase inhibitors: a patent review (2011-2017).Expert Opin Ther Pat. 2018 Jan;28(1):31-46.
8 Phase 1/2 trial of BMS-275291 in patients with human immunodeficiency virus-related Kaposi sarcoma: a multicenter trial of the AIDS Malignancy Consortium. Cancer. 2008 Mar 1;112(5):1083-8.
9 Introduction of the 4-(4-bromophenyl)benzenesulfonyl group to hydrazide analogs of Ilomastat leads to potent gelatinase B (MMP-9) inhibitors with i... Bioorg Med Chem. 2008 Sep 15;16(18):8745-59.
10 Structure-based design of potent and selective inhibitors of collagenase-3 (MMP-13). Bioorg Med Chem Lett. 2005 Feb 15;15(4):1101-6.
11 Agents in development for the treatment of diabetic nephropathy. Expert Opin Emerg Drugs. 2008 Sep;13(3):447-63.
12 Synthesis and biological evaluation of curcuminoid pyrazoles as new therapeutic agents in inflammatory bowel disease: effect on matrix metalloprote... Bioorg Med Chem. 2009 Feb 1;17(3):1290-6.
13 DP-b99 modulates matrix metalloproteinase activity and neuronal plasticity. PLoS One. 2014 Jun 11;9(6):e99789.
14 National Cancer Institute Drug Dictionary (drug id 747683).
15 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
16 Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357.
17 Neovastat, a naturally occurring multifunctional antiangiogenic drug, in phase III clinical trials. Semin Oncol. 2001 Dec;28(6):620-5.
18 Selective matrix metalloproteinase inhibition attenuates progression of left ventricular dysfunction and remodeling in dogs with chronic heart fail... Am J Physiol Heart Circ Physiol. 2006 Jun;290(6):H2522-7.
19 Matrix metalloproteinase inhibitor BB-94 (batimastat) inhibits human colon tumor growth and spread in a patient-like orthotopic model in nude mice. Cancer Res. 1994 Sep 1;54(17):4726-8.
20 Amide surrogates of matrix metalloproteinase inhibitors: Urea and sulfonamide mimics, Bioorg. Med. Chem. Lett. 7(18):2331-2336 (1997).
21 Broad spectrum matrix metalloproteinase inhibitors: an examination of succinamide hydroxamate inhibitors with P1 C alpha gem-disubstitution. Bioorg Med Chem Lett. 1998 Jun 16;8(12):1443-8.
22 Inhibition of matrix metalloproteinases by N-carboxyalkyl peptides containing extended alkyl residues At P1', Bioorg. Med. Chem. Lett. 5(6):539-542 (1995).
23 Strategies for MMP inhibition in cancer: innovations for the post-trial era. Nat Rev Cancer. 2002 Sep;2(9):657-72.
24 Discovery of gamma-lactam hydroxamic acids as selective inhibitors of tumor necrosis factor alpha converting enzyme: design, synthesis, and structu... J Med Chem. 2002 Nov 7;45(23):4954-7.